BioLife Solutions (NASDAQ:BLFS) CFO Troy Wichterman Sells 990 Shares

BioLife Solutions, Inc. (NASDAQ:BLFS) CFO Troy Wichterman sold 990 shares of the company’s stock in a transaction dated Tuesday, January 6th. The shares were sold at an average price of $25.59, for a total transaction of $25,334.10. Following the transaction, the chief financial officer owned 150,746 shares in the company, valued at $3,857,590.14. This represents a 0.65% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Troy Wichterman also recently made the following trade(s):

• On Tuesday, December 9th, Troy Wichterman sold 1,033 shares of BioLife Solutions stock. The shares were sold at an average price of $25.13, for a total transaction of $25,959.29.
• On Thursday, December 4th, Troy Wichterman sold 30,000 shares of BioLife Solutions stock. The stock was sold at an average price of $25.72, for a total transaction of $771,600.00.
• On Tuesday, November 25th, Troy Wichterman sold 584 shares of BioLife Solutions stock. The shares were sold at an average price of $26.74, for a total transaction of $15,616.16.

BioLife Solutions Price Performance

BLFS stock opened at $24.95 on Friday. BioLife Solutions, Inc. has a 1 year low of $19.10 and a 1 year high of $29.62. The company has a market cap of $1.20 billion, a P/E ratio of -356.38 and a beta of 1.93. The stock’s fifty day moving average price is $25.47 and its 200-day moving average price is $24.81.

Wall Street Analysts Forecast Growth

BLFS has been the topic of a number of recent research reports. HC Wainwright reaffirmed a “buy” rating and issued a $32.00 target price on shares of BioLife Solutions in a report on Monday, December 29th. Wall Street Zen downgraded shares of BioLife Solutions from a “buy” rating to a “hold” rating in a research report on Sunday, November 30th. Zacks Research cut BioLife Solutions from a “strong-buy” rating to a “hold” rating in a report on Monday, December 8th. Northland Securities set a $34.00 target price on BioLife Solutions in a research report on Monday. Finally, UBS Group reaffirmed a “buy” rating on shares of BioLife Solutions in a research note on Monday, December 29th. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $32.00.

Institutional Trading of BioLife Solutions

Several institutional investors and hedge funds have recently made changes to their positions in BLFS. Commonwealth of Pennsylvania Public School Empls Retrmt SYS purchased a new stake in shares of BioLife Solutions during the second quarter worth about $205,000. Forum Private Client Group LLC purchased a new stake in BioLife Solutions in the second quarter valued at $232,000. Royal Bank of Canada grew its holdings in BioLife Solutions by 762.8% during the first quarter. Royal Bank of Canada now owns 698,251 shares of the medical equipment provider’s stock worth $15,948,000 after acquiring an additional 617,320 shares during the period. State of Alaska Department of Revenue increased its holdings in shares of BioLife Solutions by 10.2% during the 2nd quarter. State of Alaska Department of Revenue now owns 22,096 shares of the medical equipment provider’s stock valued at $475,000 after purchasing an additional 2,048 shares in the last quarter. Finally, Campbell & CO Investment Adviser LLC purchased a new position in BioLife Solutions in the second quarter valued at $286,000. 93.24% of the stock is currently owned by institutional investors.

About BioLife Solutions

BioLife Solutions (NASDAQ:BLFS) specializes in biopreservation and cold chain workflow solutions for cell and gene therapies, regenerative medicine and other advanced biologics. The company develops and markets proprietary cryopreservation media and technology platforms designed to maintain cell viability and functionality during processing, storage and transport. BioLife’s product portfolio addresses critical steps in the manufacturing and distribution of cell-based products, helping life science researchers and biopharmaceutical manufacturers protect and preserve living cells.

The company’s flagship offerings include CryoStor, a family of serum-free cryopreservation media; HypoThermosol, a hypothermic storage solution for short-term cell and tissue preservation; and the ThawSTAR system, an automated cell thawing instrument that delivers controlled and reproducible warming of frozen cell therapies.